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We read with interest the paper published by Repressé and colleagues [1] . Coagulation management is a challenge during extracorporeal membrane oxygenation (ECMO) due to complex hemostatic and infl ammatory responses associated with the underlying conditions that include infection, sepsis, surgery, and/or traumatic injury [2] . Repressé and colleagues present the fi rst algorithmbased approach to bleeding in ECMO patients. However, additional perspectives are important to consider.
First, activated partial thromboplastin time or antiacti vated factor X monitoring are routinely used to monitor heparin therapy in ECMO patients, despite intraindividual and inter-individual variability [3] . Rotational thromboelasto metry (ROTEM®; TEM® International GmbH, Munich, Germany) is also increasingly used in the ICU to rapidly assess the coagulation status, including clotting factors, fi brinogen levels, and whole blood clotting [4] . Moreover, this test also facilitates fi brinolytic pathway evaluation, which cannot be easily explored by routine laboratory tests. We believe ROTEM® could be used to design an algorithm-based approach to bleeding in ECMO patients and follow fi brinogen consumption associated with hyperfi brinolysis, an important cause of bleeding. For this reason, anti-fi brinolytic agents should be considered in the multimodal approach (Figure 1) , an important point the authors omitted in their algorithm.
Second, adverse events includin g 32% venous thrombosis and a 2.5% incidence of fatal pulmonary embolism have already been reported in ECMO patients [5] . In another series, Combes and colleagues reported a 10% incidence of femoral vein and 7% incidence vena cava thrombosis [6] . Recombinant activated factor VII is associated with thromboembolic events [7] and should be used with caution until additional data help us evaluate the benefi t-to-risk administration in bleeding ECMO patients. Figure 1 
